Senti Biosciences (SNTI) vs VivoSim Labs (VIVS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
VivoSim Labs is the larger company by market cap ($5.3 million vs $4.6 million), about 1.2 times the size. VivoSim Labs converts more of its revenue into profit, with a net margin of -10567.2% versus -279263.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNTI | VIVS |
|---|---|---|
| Share price | $1.77 | $0.2608 |
| Market cap | $4.60M | $5.29M |
| 1-day change | -36.56% | -10.53% |
| YTD return | +70.19% | — |
| 1-year return | -8.76% | — |
| 5-year return | -98.23% | — |
| EPS (TTM) | $-46.20 | $-3.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.00K | $131.00K |
| Revenue growth (YoY) | — | -9.03% |
| Net income (latest FY) | $-61.44M | $-13.84M |
| Gross margin | — | 100.00% |
| Operating margin | -312631.82% | -8768.70% |
| Net margin | -279263.64% | -10567.18% |
| 52-week high | $95.04 | $3.40 |
| 52-week low | $1.71 | $0.12 |
| Distance from 52-week high | -98.14% | -92.33% |
| Analyst consensus | none | — |
| Avg. price target upside | +662.71% | — |
| Average volume | 108.98K | 15.96M |
| Shares outstanding | 2.60M | 20.28M |
| Employees | 39 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VivoSim Labs is more profitable, keeping -10567.2 cents of every revenue dollar as net income versus -279263.6 cents for Senti Biosciences.
About Senti Biosciences
SNTI stock →Senti Biosciences Holdings, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company's lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About VivoSim Labs
VIVS stock →VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 15 employees
SNTI vs VIVS FAQ
Which is bigger, Senti Biosciences or VivoSim Labs?
VivoSim Labs (VIVS) is larger, with a market capitalization of $5.29M compared with $4.60M for Senti Biosciences (SNTI).
Are Senti Biosciences and VivoSim Labs in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.